Benefits of Immunoglobulin (Ig) Replacement Therapy for Primary and Secondary Immunodeficiency in Chronic Rhinosinusitis

• Published in: Otolaryngology-head and neck surgery Vol. 170; no. 3; pp. 968 - 971
• Main Authors: Garvey, Emily A., Arielle Best, Keisha, Naimi, Bita, Duffy, Alexander, Hannikainen, Paavali, Kahn, Chase, Farquhar, Douglas, Rosen, Marc, Rabinowitz, Mindy, Fung, Shirley, Toskala, Elina, Nyquist, Gurston
• Format: Journal Article
• Language: English
• Published: England 01-03-2024
• Subjects: Chronic Disease; chronic rhinosinusitis; Humans; ig replacement therapy; immunodeficiency; Immunoglobulins - therapeutic use; Immunologic Deficiency Syndromes - drug therapy; Immunologic Deficiency Syndromes - therapy; Rhinitis - complications; Rhinitis - drug therapy; Rhinosinusitis; Sinusitis - complications; Sinusitis - diagnosis; Sinusitis - therapy; chronic rhinosinusitis; ig replacement therapy; immunodeficiency
• ISSN: 0194-5998; 1097-6817
• DOI: 10.1002/ohn.579

This is the first study to examine chronic rhinosinusitis (CRS) outcomes after starting immunoglobulin (Ig) replacement therapy for patients with primary (PID) and secondary immunodeficiency (SID). This is a retrospective review of patients diagnosed with CRS from 2018 to 2022 prior to initiating Ig therapy for the treatment of PID or SID. Outcomes included medication use and Sinonasal Outcome Test (SNOT‐22) scores. Ten patients met the inclusion criteria. PID and SID patients had a decrease in antibiotics (PID: 9.40 to 3.20, P = .05, SID: 8.20 to 2.00, P = .04) and steroids (PID: (5.40 to 0.60; P = .06; SID: 2.20 to 0.20, P = .047) prescribed in the year after Ig compared to the year prior. Patients with SID had a decrease in mean SNOT‐22 scores by 12 months after Ig (47.50 to 20.50, P = 0.03). Patients receiving Ig for PID and SID showed decreased medication use and SID patients experienced subjective improvement in CRS symptoms in year‐over‐year comparison.